About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Rapid-Acting Insulin Market Size, Analysis, Trends,Share to 2030
Rapid-Acting Insulin Market

Rapid-Acting Insulin Market Size, Share & Trends Analysis Report By Product Type (Insulin Lispro, Insulin Aspart, Insulin Glulisine), By Disease (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Provider) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI2121DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Rapid-Acting Insulin Market Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    5. U.S.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Insulin Lispro
          1. By Value
        3. Insulin Aspart
          1. By Value
        4. Insulin Glulisine
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Type 1 Diabetes
          1. By Value
        3. Type 2 Diabetes
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Drug Stores & Retail Pharmacies
          1. By Value
        4. Online Provider
          1. By Value
    6. Canada
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    5. U.K.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Insulin Lispro
          1. By Value
        3. Insulin Aspart
          1. By Value
        4. Insulin Glulisine
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Type 1 Diabetes
          1. By Value
        3. Type 2 Diabetes
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Drug Stores & Retail Pharmacies
          1. By Value
        4. Online Provider
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    5. China
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Insulin Lispro
          1. By Value
        3. Insulin Aspart
          1. By Value
        4. Insulin Glulisine
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Type 1 Diabetes
          1. By Value
        3. Type 2 Diabetes
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Drug Stores & Retail Pharmacies
          1. By Value
        4. Online Provider
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    5. UAE
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Insulin Lispro
          1. By Value
        3. Insulin Aspart
          1. By Value
        4. Insulin Glulisine
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Type 1 Diabetes
          1. By Value
        3. Type 2 Diabetes
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Drug Stores & Retail Pharmacies
          1. By Value
        4. Online Provider
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Insulin Lispro
        1. By Value
      3. Insulin Aspart
        1. By Value
      4. Insulin Glulisine
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Type 1 Diabetes
        1. By Value
      3. Type 2 Diabetes
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Drug Stores & Retail Pharmacies
        1. By Value
      4. Online Provider
        1. By Value
    5. Brazil
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Insulin Lispro
          1. By Value
        3. Insulin Aspart
          1. By Value
        4. Insulin Glulisine
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Type 1 Diabetes
          1. By Value
        3. Type 2 Diabetes
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Drug Stores & Retail Pharmacies
          1. By Value
        4. Online Provider
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Rapid-Acting Insulin Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Sanofi S.A.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novo Nordisk A/S
    3. Eli Lilly And Company
    4. Mannkind Corporation
    5. Adocia Sas
    6. Biocon Limited
    7. Wockhardt Ltd.
    8. Gan & Lee Pharmaceuticals
    9. Geropharm LLC
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Market Overview The global short-acting insulin market size is to grow to USD 10288 million by 2030 at a CAGR of 2% from the early figures of USD 9257 million in 2021. The short-acting insulin market is largely consolidated, with Sanofi, Novo Nord
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.